Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Alder Biopharmaceuticals

Thumbnail
November 08, 2019

2020 CGRP sales hopes look far fetched

Thumbnail
October 14, 2019

Lack of drive could slow down Reyvow sales

Article image
Vantage logo
October 08, 2019

Deal-depressed third quarter leaves nowhere to hide

Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.

Article image
Vantage logo
September 16, 2019

Alder won’t solve Lundbeck’s headaches

Lundbeck needed a deal, but it could struggle against strong competition in migraine.

Article image
Vantage logo
August 30, 2019

Upcoming events – pivotal tests approach for Lilly and Biohaven

Lilly is awaiting the first set of pivotal data with the cytokine agent it bought from Armo last year, while Biohaven heads for migraine catalysts.

Article image
Vantage logo
May 02, 2019

Faint hope for Alder as Teva bucks dismal migraine trend

Alder hopes soon to launch its migraine drug eptinezumab, and will nervously have been watching the first full quarter’s sales of three similarly acting drugs.

Article image
Vantage logo
April 12, 2019

Upcoming events – a legal verdict for Enbrel and a clinical one for Cymabay

Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.

Article image
Vantage logo
March 21, 2019

No, aducanumab is not an Alzheimer’s drug either

Failure at a futility analysis blows a big hole in Biogen's pipeline. Can the company buy in growth or will its valuation sink enough for it to become a target?

Article image
Vantage logo
February 07, 2019

Lilly hopes volume can make up for late migraine entry

In a constrained pricing environment a volume play could help sales of Lilly's Emgality as it takes on Amgen’s Aimovig and Teva’s Ajovy.

Article image
Vantage logo
September 28, 2018

Upcoming events – Sage and Biohaven await pivotal data

Sage Therapeutics will report the first pivotal data with its oral postpartum depression candidate, while Biohaven Pharma transfers its hopes to a faster-acting migraine…

Article image
Vantage logo
September 17, 2018

Teva tries to make something out of nothing with Ajovy approval

Competition in the CGRP migraine space has left both Teva and Amgen willing to take hits on sales to hook new patients.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.